PT  - JOURNAL ARTICLE
AU  - AKITAKE, MASAKAZU
AU  - YAMAGUCHI, AKITO
AU  - SHIOTA, MASAKI
AU  - IMADA, KENJIRO
AU  - TATSUGAMI, KATSUNORI
AU  - YOKOMIZO, AKIRA
AU  - NAITO, SEIJI
AU  - ETO, MASATOSHI
TI  - Predictive Factors for Residual Cancer in Second Transurethral Resection for Non-muscle-invasive Bladder Cancer
AID  - 10.21873/anticanres.13598
DP  - 2019 Aug 01
TA  - Anticancer Research
PG  - 4325--4328
VI  - 39
IP  - 8
4099  - http://ar.iiarjournals.org/content/39/8/4325.short
4100  - http://ar.iiarjournals.org/content/39/8/4325.full
SO  - Anticancer Res2019 Aug 01; 39
AB  - Background/Aim: The significance of second transurethral resection (TUR), and identification of predictive factors for residual cancer remain unrevealed. This study aimed to find residual cancer and up-staging rates, as well as predictive factors for residual cancer, in patients who undergo second TUR for non-muscle-invasive bladder cancer (NMIBC). Patients and Methods: Patients who underwent second TURs for NMIBC between 2015 and 2017, were included in the study and their clinicopathological characteristics were analyzed for predictors of residual cancer. Results: Among 143 Japanese patients whose tumors were initially diagnosed as high-risk NMIBC, residual cancers detected at second TURs were, Tis: n=22 (15.4%), Ta: n=15 (10.5%) and T1: n=29 (20.3%). No patients showed up-staging from NMIBC to MIBC. The presence of carcinoma-in situ at initial TUR was an independent risk factor for any residual cancer (Tis, Ta and T1), non-flat residual cancer (Ta and T1), and flat residual cancer (Tis). Conclusion: The presence of carcinoma-in situ is suggested to be an independent predictor of residual cancer. This may help guide decisions to perform second TUR.